Metabolism and Excretion of [14C]ASP3082 in Healthy Adult Male Participants

Phase 1, open-label, single-arm trial of setidegrasib in cancer, sponsored by Astellas Pharma. Primary endpoints: Area under the concentration-time curve from the time of dosing extrapolated to time infinity up to 21 days, Area under the concentration-time curve from the time of dosing to the last measurable concentration up to 21 days and 6 more. Started Aug 2026; status: completed.